Trials / Completed
CompletedNCT02270034
Study to Evaluate Safety and Activity of Crizotinib With Temozolomide and Radiotherapy in Newly Diagnosed Glioblastoma
Phase Ib, Open-label, Multicenter, Dose-escalation Study Followed by an Extension Phase to Evaluate the Safety and Activity of the Combination of Crizotinib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Glioblastoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 38 (actual)
- Sponsor
- Grupo Español de Investigación en Neurooncología · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This multicenter, open-label, phase Ib trial aims to assess the safety and activity and safety of crizotinib (in combination with radiotherapy and temozolomide) in adult patients with newly diagnosed glioblastoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Crizotinib | Crizotinib is added to Stupp method |
Timeline
- Start date
- 2014-08-13
- Primary completion
- 2020-10-26
- Completion
- 2020-10-26
- First posted
- 2014-10-21
- Last updated
- 2022-03-10
Locations
4 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT02270034. Inclusion in this directory is not an endorsement.